Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $105.11 (market cap $8.88B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.16 (market cap $298.34M). The key difference: Kymera Therapeutics Inc. Common Stock is far larger — about 29.8× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Kymera Therapeutics Inc. Common Stock is trading nearer its 52-week high, YieldMax Magnificent 7 Fund of Option Income ETFs nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| KYMR | YMAG | |
|---|---|---|
Market Cap | $8.88B | $298.34M |
Volume | 1,028,790 | 1,081,943 |
Sector | Health | Income / Options Overlay |
52-Week High | $127.31 | $15.68 |
52-Week Low | $55.80 | $10.76 |
Typical Hold Time | 0 Days | 62 Days |
Enterprise Value | $8.27B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
YMAG trades at $11.55, up 0.7% today, with a neutral technical signal and bullish moving averages. The ETF maintains a consistent weekly dividend distribution schedule, with recent payouts ranging from $0.07 to $0.11 per share. RSI levels show mixed signals with short-term overbought conditions. Support and resistance levels are tightly clustered around $11-$12, indicating potential for near-term consolidation.
The outlook remains balanced with high distribution yields providing income appeal, though technical indicators suggest limited near-term momentum. Key risks include NAV stability during earnings periods and dependency on underlying option strategies. Analyst coverage is limited, requiring careful monitoring of component fund performance and distribution sustainability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
